Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Cash flows from operating activities:          
Net loss     $ (367,216) $ (102,288)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization     25,602 9,524  
Stock-based compensation     26,917 6,216  
Goodwill impairment $ 229,500   229,500    
Change in fair value of warrant liability       56,576  
Change in fair value of subscription agreement       474  
Amortization (accretion) of discount on investments     390 1,304  
Amortization of debt financing cost       9  
Amortization of deferred costs on convertible notes     39    
Provision for bad debt     554 164 $ 447
Acquired in-process research and development   $ 10,400   10,400  
Loss (gain) on disposal of property and equipment     156 (7)  
Foreign exchange (gains) losses on intercompany transactions, net     443    
Net increase (decrease) in accrued interest related to marketable securities     917 (1,062)  
Net unrealized (gain) loss on equity investment (3,400)   5,080    
Net unrealized (gain) loss on other investments     800 (517)  
Deferred tax benefit     (2,188) (32,535)  
Change in fair value of contingent consideration (100)   4    
Foreign currency transaction (gain) loss     (13)    
Changes in operating assets and liabilities:          
Accounts receivable     8,250 (3,584)  
Inventory     (25,384) (6,635)  
Prepaid expenses and other current assets     (2,994) (3,732)  
Other assets     1,117 (170)  
Accounts payable     (2,767) (155)  
Accrued expenses and other current liabilities     (7,337) (5,119)  
Customer deposits     (1,412) (1,372)  
Current portion of deferred revenue     (70) 693  
Change in right of use assets and lease liabilities, net     (1,467) (92)  
Other liabilities     30    
Net cash used in operating activities     (111,049) (71,908)  
Cash flows from investing activities:          
Purchases of property and equipment     (6,747) (1,355)  
Purchase of other investments       (3,620)  
Proceeds from sale of property and equipment     6    
Purchase of marketable securities     (126,771) (281,438)  
Proceeds from sales and maturities of marketable securities     177,150 66,741  
Cash paid to acquire in-process research and development       (6,050)  
Cash paid for acquisitions, net of cash acquired     (23) (161,837)  
Net cash provided by (used in) investing activities     43,615 (387,559)  
Cash flows from financing activities:          
Proceeds from the exercise of stock options     1,266 3,665  
Proceeds from the exercise of stock warrants       170,665  
Payment of taxes related to net share settlement upon vesting of restricted stock units     (191) (145)  
Repayment of loans     (231)    
Proceeds from issuance of convertible notes     115,000    
Costs incurred in connection with the issuance of convertible notes     (3,619)    
Repayment of term loan       (10,000)  
Net cash provided by financing activities     112,225 164,185  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (819) 20  
Net increase (decrease) in cash, cash equivalents, and restricted cash     43,972 (295,262)  
Cash, cash equivalents, and restricted cash at beginning of period     68,258 484,137 484,137
Cash, cash equivalents, and restricted cash at end of period 112,230 188,875 112,230 188,875 68,258
Supplemental disclosures of cash flow information          
Cash and cash equivalents 107,966 188,199 107,966 188,199 65,017
Restricted cash included in other current assets 3,152   3,152    
Restricted cash included in other noncurrent assets 1,112 676 1,112 676  
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 112,230 188,875 112,230 188,875 $ 68,258
Supplemental cash flow information:          
Interest paid       125  
Taxes paid       150  
Non-cash investing and financing activities:          
Net unrealized (gain) loss on investments     29 4  
Exercise of private placement warrants       149,904  
Common Stock issued for acquisitions   49,142   208,989  
Common Stock issued for acquisition of in-process research and development   $ 4,300   4,300  
Common Stock issued for settlement of contingent consideration     500    
Cash held back in acquisitions       50  
Additions to right of use assets and lease liabilities     7,784 852  
Purchase of property and equipment included in accounts payable     1,022    
Purchase of property and equipment included in accrued expense       33  
Contingent consideration in connection with acquisitions       $ 6  
Transfers from property and equipment to inventory     1,954    
Transfers from inventory to property and equipment     1,531    
Deferred contract costs     $ 1,341